HK1206283A1 - Treatment of multiple sclerosis with anti-cd19 antibody -cd19 - Google Patents
Treatment of multiple sclerosis with anti-cd19 antibody -cd19Info
- Publication number
- HK1206283A1 HK1206283A1 HK15107127.4A HK15107127A HK1206283A1 HK 1206283 A1 HK1206283 A1 HK 1206283A1 HK 15107127 A HK15107127 A HK 15107127A HK 1206283 A1 HK1206283 A1 HK 1206283A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- antibody
- treatment
- multiple sclerosis
- sclerosis
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261609704P | 2012-03-12 | 2012-03-12 | |
PCT/US2013/030247 WO2013138244A2 (fr) | 2012-03-12 | 2013-03-11 | Traitement de la sclérose en plaques par un anticorps anti-cd19 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1206283A1 true HK1206283A1 (en) | 2016-01-08 |
Family
ID=49161934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15107127.4A HK1206283A1 (en) | 2012-03-12 | 2015-07-27 | Treatment of multiple sclerosis with anti-cd19 antibody -cd19 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20150044168A1 (fr) |
EP (1) | EP2827902A4 (fr) |
JP (1) | JP2015515456A (fr) |
KR (1) | KR20140148411A (fr) |
CN (1) | CN104640560A (fr) |
AU (1) | AU2013232386A1 (fr) |
CA (1) | CA2866943A1 (fr) |
HK (1) | HK1206283A1 (fr) |
MX (1) | MX2014010987A (fr) |
RU (1) | RU2014141056A (fr) |
WO (1) | WO2013138244A2 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104450747B (zh) * | 2014-09-23 | 2018-02-09 | 武汉纽福斯生物科技有限公司 | 用于治疗Leber遗传性视神经病变的重组腺相关病毒‑NADH脱氢酶亚单位4基因全长以及药剂 |
US10493139B2 (en) | 2015-07-24 | 2019-12-03 | Innovative Cellular Therapeutics CO., LTD. | Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor |
WO2017015783A1 (fr) * | 2015-07-24 | 2017-02-02 | Shanghai Sidansai Biotechnology Co., Ltd | Anticorps humanisé anti-cd19 et utilisation associée |
MX2019010174A (es) | 2017-03-26 | 2019-10-15 | Mapi Pharma Ltd | Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple. |
EP3959241A4 (fr) * | 2019-04-24 | 2023-01-25 | Viela Bio, Inc. | Utilisation d'un anticorps anti-cd19 pour traiter une maladie auto-immune |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1648512A4 (fr) * | 2003-07-31 | 2009-01-21 | Immunomedics Inc | Anticorps anti-cd19 |
WO2005117978A2 (fr) * | 2004-06-04 | 2005-12-15 | Genentech, Inc. | Methode de traitement de la sclerose en plaques |
AU2007285976B2 (en) * | 2006-08-14 | 2011-08-18 | Xencor, Inc | Optimized antibodies that target CD19 |
MX2009002414A (es) * | 2006-09-08 | 2009-05-20 | Medimmune Llc | Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria. |
TW201014605A (en) * | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
KR20110125664A (ko) * | 2009-03-06 | 2011-11-21 | 메디뮨 엘엘씨 | 인간화된 항-cd19 항체 제형 |
-
2013
- 2013-03-11 CN CN201380013506.XA patent/CN104640560A/zh active Pending
- 2013-03-11 EP EP13760788.3A patent/EP2827902A4/fr not_active Withdrawn
- 2013-03-11 WO PCT/US2013/030247 patent/WO2013138244A2/fr active Application Filing
- 2013-03-11 US US14/384,714 patent/US20150044168A1/en not_active Abandoned
- 2013-03-11 AU AU2013232386A patent/AU2013232386A1/en not_active Abandoned
- 2013-03-11 MX MX2014010987A patent/MX2014010987A/es unknown
- 2013-03-11 KR KR1020147028131A patent/KR20140148411A/ko not_active Application Discontinuation
- 2013-03-11 JP JP2015500495A patent/JP2015515456A/ja active Pending
- 2013-03-11 RU RU2014141056A patent/RU2014141056A/ru not_active Application Discontinuation
- 2013-03-11 CA CA2866943A patent/CA2866943A1/fr not_active Abandoned
-
2015
- 2015-07-27 HK HK15107127.4A patent/HK1206283A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
MX2014010987A (es) | 2015-03-03 |
RU2014141056A (ru) | 2016-05-10 |
WO2013138244A3 (fr) | 2014-12-24 |
US20150044168A1 (en) | 2015-02-12 |
EP2827902A2 (fr) | 2015-01-28 |
KR20140148411A (ko) | 2014-12-31 |
WO2013138244A8 (fr) | 2014-09-18 |
AU2013232386A1 (en) | 2014-10-16 |
CA2866943A1 (fr) | 2013-09-19 |
CN104640560A (zh) | 2015-05-20 |
JP2015515456A (ja) | 2015-05-28 |
AU2013232386A8 (en) | 2014-10-23 |
WO2013138244A2 (fr) | 2013-09-19 |
EP2827902A4 (fr) | 2016-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2723384A4 (fr) | Traitement de protéinopathies | |
HK1207583A1 (en) | Use of biotin for the treatment of multiple sclerosis | |
ZA201406082B (en) | Use of ccr3-inhibitors | |
IL237460B (en) | Treatment of post-traumatic stress disorder with an isolated microbacterium | |
EP2906580A4 (fr) | Traitement de la sclérose latérale amyotrophique | |
HK1211986A1 (en) | Platelet targeted treatment | |
EP2881113A4 (fr) | Nouvelle application de la pogostone | |
HK1206283A1 (en) | Treatment of multiple sclerosis with anti-cd19 antibody -cd19 | |
HK1204629A1 (en) | Treatment of mucositis with immunoglobulin | |
ZA201408062B (en) | Compositions and methods for the treatment of multiple sclerosis | |
EP2892529A4 (fr) | Utilisations de (-)-perhexiline | |
GB201207907D0 (en) | Treatment of depression | |
HK1210421A1 (en) | Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders -4--20--3- | |
GB201218263D0 (en) | Treatment of autism | |
GB201221118D0 (en) | Methods of treatment | |
GB201216748D0 (en) | Methods of treatment | |
GB201216740D0 (en) | Methods of treatment | |
GB201206324D0 (en) | Methods of treatment | |
GB201206330D0 (en) | Methods of treatment | |
GB201206326D0 (en) | Methods of treatment | |
GB201206325D0 (en) | Methods of treatment | |
GB201321600D0 (en) | Method of cleaning | |
TWM433525U (en) | Structure of calorifier | |
GB201211135D0 (en) | Treatment | |
GB201208690D0 (en) | Treatment |